1. Scrip
  2. >>Business
  3. >>Deals

Sarepta Gobbles Up Gene Therapy Partner Myonexus After Early Data Win In Muscular Dystrophy

 
• By Jo Shorthouse

Sarepta Therapeutics has wasted no time in buying out partner Myonexus, swallowing up five extra clinical candidates, after studies of its lead gene therapy for limb-girdle muscular dystrophy showed positive results.

Fish
Sarepta is following the money with Myonexus Buy • Source: Shutterstock

Sarepta Therapeutics Inc. shares rose 10% on the news that it is to buy partner Myonexus Therapeutics Inc. for $165m on the back of positive Phase I/II data from the three-patient study of its gene therapy, MYO-101, in limb-girdle muscular dystrophy (LGMD).

Although from just three patients, with another six patients to dose, JMP Securities analysts were impressed by the initial data,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

More from Business